These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 22168789

  • 1. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W.
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
    [Abstract] [Full Text] [Related]

  • 2. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 3. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Mar; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.
    Antivir Ther; 2009 Mar; 14(8):1165-74. PubMed ID: 20032546
    [Abstract] [Full Text] [Related]

  • 5. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F, ANRS HB06 PEGAN Study Group.
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
    Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS.
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
    [Abstract] [Full Text] [Related]

  • 7. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Sep; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 8. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 9. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, di Paolo D, Demelia L, Sorbello O, Nosotti L, Angelico M.
    Antivir Ther; 2013 Dec 14; 18(1):57-64. PubMed ID: 22872648
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
    Suh DJ, Lee HC, Byun KS, Cho M, Kweon YO, Tak WY, Chon CY, Koh KC, Lee YS.
    Antivir Ther; 2013 Dec 14; 18(6):765-73. PubMed ID: 23900457
    [Abstract] [Full Text] [Related]

  • 12. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.
    Antivir Ther; 2011 Dec 14; 16(5):629-37. PubMed ID: 21817184
    [Abstract] [Full Text] [Related]

  • 13. Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
    Wang YD, Zhao CY, Wang W, Shen C, Lu HZ, Zhang L, Yu WY, Zhou JY, Yan WZ.
    Hepatogastroenterology; 2012 May 14; 59(115):680-6. PubMed ID: 22441104
    [Abstract] [Full Text] [Related]

  • 14. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB, Golge N, Akin MS.
    Eur J Gastroenterol Hepatol; 2013 Nov 14; 25(11):1312-6. PubMed ID: 23652913
    [Abstract] [Full Text] [Related]

  • 15. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P, Viganò M, Colombo M.
    Liver Int; 2013 Feb 14; 33 Suppl 1():157-63. PubMed ID: 23286860
    [Abstract] [Full Text] [Related]

  • 16. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X, Yu JX, Xie L, Ma WJ, Wang LH.
    Ann Hepatol; 2013 Feb 14; 16(6):888-892. PubMed ID: 29055925
    [Abstract] [Full Text] [Related]

  • 17. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct 14; 20(10):737-41. PubMed ID: 23207332
    [Abstract] [Full Text] [Related]

  • 18. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
    Chan HL, Wong VW, Chim AM, Wong GL, Chan HY, Sung JJ.
    Antivir Ther; 2008 Oct 14; 13(4):555-62. PubMed ID: 18672534
    [Abstract] [Full Text] [Related]

  • 19. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H, Wang C, Zhang Y, Wei S, Li X, Zhang Z.
    J Gastroenterol Hepatol; 2016 Dec 14; 31(12):1963-1970. PubMed ID: 27075693
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD, Chen XF, Zhou Y, Chen XP.
    J Viral Hepat; 2017 Nov 14; 24 Suppl 1():36-42. PubMed ID: 29082651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.